Pick Today's Price Range Low-High... Just for Fun, page-57

If approved, the next step will be revenue, and MSB bleeds cash especially when running trials.



ROFL .... so if the FDA granted Mesoblast an AA for CHF you don't think a global partnership deal for this indication would emerge with huge $$ ? Here's a reminder of how much money the last one saw deposited into Mesoblast's bank account and that was prior to the DREAM-HF phase 3 trial so one can only imagine what the size of said CHF partnership would be on the back of an FDA Accelerated Approval for Rexlemestrocel-L for CHF ..... the mind boggles



...... and I hate to burst your bubble but license fees / upfront payments for a partnership count as revenue so I think Mesoblast would be more than fine off the back of an FDA AA for CHF - just sayin'



https://www.fiercebiotech.com/biotech/cephalon-and-mesoblast-form-strategic-alliance

Cephalon and Mesoblast form strategic alliance


Under the terms of the Development and Commercialization Agreement between the companies, in exchange for exclusive world-wide rights to commercialize specific products based on Mesoblast's proprietary adult stem cell technology platform, Cephalon will make an upfront payment to Mesoblast totaling $130 million


In addition, under the terms of a Stock Purchase Agreement and a Subscription Deed, Cephalon will make an equity investment to purchase a 19.99% stake in Mesoblast at A$4.35 per share, totaling approximately $220 million. This price represents a 45% premium to the last 30 days' volume weighted average price for Mesoblast shares. Cephalon has entered into a standstill agreement to limit its investment to 19.99% of Mesoblast common stock for the next 12 months, with a right to maintain its equity stake on a top up basis, subject to the Australian Securities Exchange rules. Cephalon COO J. Kevin Buchi will join the Mesoblast Board of Directors, effective immediately.




https://www.biospace.com/article/re...ake-drug-rights-in-potential-2-billion-deal-/


Cephalon, Inc. Buys Mesoblast Limited Stake, Drug Rights in Potential $2 Billion Deal


Agreement Provides Cephalon with Global Rights in Three Treatment Areas to Products Derived from Mesoblast's Innovative Adult Mesenchymal Precursor Stem Cell Technology